Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Biorestorative Therapies Inc (BRTX)

Biorestorative Therapies Inc (BRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,147
  • Shares Outstanding, K 3,648
  • Annual Sales, $ 50 K
  • Annual Income, $ -44,300 K
  • 60-Month Beta 63.34
  • Price/Sales 90.94
  • Price/Cash Flow N/A
  • Price/Book 0.67
Trade BRTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.30
  • Number of Estimates 1
  • High Estimate -1.30
  • Low Estimate -1.30
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.60 +16.15%
on 12/29/22
3.27 -7.65%
on 01/13/23
+0.03 (+1.00%)
since 12/23/22
3-Month
2.55 +18.43%
on 11/23/22
4.40 -31.36%
on 12/05/22
-0.38 (-11.18%)
since 10/26/22
52-Week
2.46 +22.76%
on 09/27/22
5.97 -49.46%
on 04/05/22
-0.57 (-15.88%)
since 01/26/22

Most Recent Stories

More News
BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event

Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies,...

BRTX : 3.02 (-1.17%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 27.85 (-0.21%)
OCEL : 0.0178 (-1.11%)
BRTX : 3.02 (-1.17%)
MDXG : 3.81 (+7.32%)
NNVC : 1.4500 (unch)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 0.0178 (-1.11%)
BRTX : 3.02 (-1.17%)
MDXG : 3.81 (+7.32%)
NNVC : 1.4500 (unch)
VCEL : 27.85 (-0.21%)
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...

BRTX : 3.02 (-1.17%)
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...

BRTX : 3.02 (-1.17%)
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

-- First Site Will Enroll First Patient in the Clinical Study--  MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....

BRTX : 3.02 (-1.17%)
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

MELVILLE, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...

BRTX : 3.02 (-1.17%)
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...

BRTX : 3.02 (-1.17%)
BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program

MELVILLE, N.Y., March 10, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...

BRTX : 3.02 (-1.17%)
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program

Notice of Allowance Grants Protection for BioRestorative’s Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease MELVILLE, N.Y., Feb. 16, 2022 ...

BRTX : 3.02 (-1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM)...

See More

Key Turning Points

3rd Resistance Point 3.20
2nd Resistance Point 3.17
1st Resistance Point 3.09
Last Price 3.02
1st Support Level 2.98
2nd Support Level 2.95
3rd Support Level 2.87

See More

52-Week High 5.97
Fibonacci 61.8% 4.63
Fibonacci 50% 4.22
Fibonacci 38.2% 3.80
Last Price 3.02
52-Week Low 2.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar